The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinicopathological and molecular biological characteristics of early-onset stage II/III colorectal adenocarcinoma: An analysis of 25 studies with 47,184 patients (pts) in the adjuvant colon cancer end points (ACCENT) database.
 
Zhaohui Jin
No Relationships to Disclose
 
Jesse G. Dixon
No Relationships to Disclose
 
Hiral D. Parekh
No Relationships to Disclose
 
Steven R Alberts
No Relationships to Disclose
 
Greg Yothers
Employment - Mountainview Pediatrics (I)
Consulting or Advisory Role - Orbus Therapeutics; Pharmacyclics
 
Carmen Joseph Allegra
No Relationships to Disclose
 
Rachel Kerr
No Relationships to Disclose
 
Daniel G. Haller
Speakers' Bureau - Amgen; Exelixis; Lilly; Taiho Pharmaceutical
 
Aimery De Gramont
No Relationships to Disclose
 
Takayuki Yoshino
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); GlaxoSmithKline (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); PAREXEL International Inc. (Inst); Sanofi (Inst); Sumitomo Dainippon (Inst)
 
Eric Van Cutsem
Consulting or Advisory Role - Array BioPharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Celgene; Halozyme; Lilly; Merck KGaA; Merck Sharp & Dohme; Novartis; Roche; SERVIER
Research Funding - amgen (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Ipsen (Inst); Lilly (Inst); Merck (Inst); Merck KGaA (Inst); Novartis (Inst); Roche (Inst); SERVIER (Inst)
 
Chris Twelves
No Relationships to Disclose
 
Julien Taieb
No Relationships to Disclose
 
Leonard B. Saltz
Research Funding - Taiho Pharmaceutical
 
Jean-François Seitz
No Relationships to Disclose
 
Thierry Andre
Honoraria - AMGEN; Bayer; Bristol-Myers Squibb; Pierre Fabre; Roche/Genentech; Sanofi; SERVIER; Ventana Medical Systems
Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Clovis Oncology; Gastrointestinal Cancers Advice; Gastrointestinal Cancers Advice; HalioDX; MSD Oncology; Roche/Genentech; SERVIER; Tesaro
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Bristol-Myers Squibb; MSD Oncology; MSD Oncology; MSD Oncology; Roche; Roche/Genentech; Ventana Medical Systems
 
Amit Mahipal
Honoraria - Ipsen; Merck
Research Funding - Astellas Scientific and Medical Affairs Inc (Inst); Karyopharm Therapeutics (Inst); Novartis (Inst); Taiho Pharmaceutical
 
Richard M. Goldberg
Honoraria - Amgen
Consulting or Advisory Role - Merck; Merck KGaA; Novartis; Taiho Pharmaceutical
Research Funding - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Amgen; Merck; Merck KGaA
 
Qian Shi
Stock and Other Ownership Interests - Amgen; Johnson & Johnson
Consulting or Advisory Role - Yiviva
Research Funding - Celgene (Inst); Roche/Genentech (Inst)
 
Thomas J. George
Research Funding - AstraZeneca/MedImmune (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Ipsen (Inst); Lilly (Inst); Merck (Inst); Newlink Genetics (Inst); Pharmacyclics (Inst); Seagen (Inst); Tesaro (Inst)